From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:1fcy.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:1fcy.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_1fcy| PDB=1fcy | SCENE= }} | | {{STRUCTURE_1fcy| PDB=1fcy | SCENE= }} |
| | | | |
| - | '''ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA-SELECTIVE RETINOID CD564'''
| + | ===ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA-SELECTIVE RETINOID CD564=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | The human retinoic acid receptor (hRAR) belongs to the family of nuclear receptors that regulate transcription in a ligand-dependent way. The isotypes RARalpha,beta and gamma are distinct pharmacological targets for retinoids that are involved in the treatment of various skin diseases and cancers, in particular breast cancer and acute promyelocytic leukemia. Therefore, synthetic retinoids have been developed aiming at isotype selectivity and reduced side-effects. We report the crystal structures of three complexes of the hRARgamma ligand-binding domain (LBD) bound to agonist retinoids that possess selectivity either for RARgamma (BMS184394) or for RARbeta/gamma (CD564), or that are potent for all RAR-isotypes (panagonist BMS181156). The high resolution data (1.3-1. 5 A) provide a description at the atomic level of the ligand pocket revealing the molecular determinants for the different degrees of ligand selectivity. The comparison of the complexes of the chemically closely related retinoids BMS184394 and CD564 shows that the side-chain of Met272 adopts different conformations depending on the presence of a hydrogen bond between its sulfur atom and the ligand. This accounts for their different isotype selectivity. On the other hand, the difference between the pan- and the RARbeta, gamma-selective agonist is probably due to a steric discrimination at the level of the 2-naphthoic acid moiety of CD564. Based on this study, we propose a model for a complex with the RARgamma-specific agonist CD666 that shows the possible applications for structure-based drug design of RAR isotype-selective retinoids. | + | The line below this paragraph, {{ABSTRACT_PUBMED_10964567}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 10964567 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_10964567}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 33: |
Line 37: |
| | [[Category: Structural genomic]] | | [[Category: Structural genomic]] |
| | [[Category: Structural proteomics in europe]] | | [[Category: Structural proteomics in europe]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Apr 13 08:06:27 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 03:03:56 2008'' |
Revision as of 00:03, 1 July 2008
Template:STRUCTURE 1fcy
ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA-SELECTIVE RETINOID CD564
Template:ABSTRACT PUBMED 10964567
About this Structure
1FCY is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structural basis for isotype selectivity of the human retinoic acid nuclear receptor., Klaholz BP, Mitschler A, Moras D, J Mol Biol. 2000 Sep 8;302(1):155-70. PMID:10964567
Page seeded by OCA on Tue Jul 1 03:03:56 2008
